Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An announcement from Kiniksa Pharmaceuticals (KNSA) is now available.
Kiniksa Pharmaceuticals, Ltd. has announced the launch of a Phase 2b clinical trial for abiprubart in Sjogren’s Disease, along with promising topline data from its rheumatoid arthritis trial. The company also anticipates maintaining a positive cash flow within its current operations. This information, aimed at investors, has been made available through a press release and a detailed investor presentation on their website.
See more insights into KNSA stock on TipRanks’ Stock Analysis page.